Einloggen

Thematische Bibliographien / ARTHRITIS DRUG

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile
Konferenzberichte
Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „ARTHRITIS DRUG“

Autor: Grafiati

Veröffentlicht am 11. September 2023

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "ARTHRITIS DRUG" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "ARTHRITIS DRUG"

1

Gupta, Anuradha, Jungmi Lee, Torsha Ghosh, Van Quy Nguyen, Anup Dey, Been Yoon, Wooram Um und Jae Hyung Park. „Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis“. Pharmaceutics 14, Nr. 3 (28.02.2022): 540. http://dx.doi.org/10.3390/pharmaceutics14030540.

Der volle Inhalt der Quelle

Annotation:

Rheumatoid arthritis (RA) and osteoarthritis (OA) are disabling musculoskeletal disorders that affect joints and cartilage and may lead to bone degeneration. Conventional delivery of anti-arthritic agents is limited due to short intra-articular half-life and toxicities. Innovations in polymer chemistry have led to advancements in hydrogel technology, offering a versatile drug delivery platform exhibiting tissue-like properties with tunable drug loading and high residence time properties This review discusses the advantages and drawbacks of polymeric materials along with their modifications as well as their applications for fabricating hydrogels loaded with therapeutic agents (small molecule drugs, immunotherapeutic agents, and cells). Emphasis is given to the biological potentialities of hydrogel hybrid systems/micro-and nanotechnology-integrated hydrogels as promising tools. Applications for facile tuning of therapeutic drug loading, maintaining long-term release, and consequently improving therapeutic outcome and patient compliance in arthritis are detailed. This review also suggests the advantages, challenges, and future perspectives of hydrogels loaded with anti-arthritic agents with high therapeutic potential that may alter the landscape of currently available arthritis treatment modalities.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Moudgil, Kamal D., Hemalatha Nanjaiah, Shivaprasad H. Venkatesha und Rakeshchandra R. Meka. „Nanotechnology-based drug delivery for targeted therapy of autoimmune arthritis improves the therapeutic profile of anti-arthritis drugs“. Journal of Immunology 210, Nr. 1_Supplement (01.05.2023): 165.14. http://dx.doi.org/10.4049/jimmunol.210.supp.165.14.

Der volle Inhalt der Quelle

Annotation:

Abstract Rheumatoid arthritis (RA) is among the major human autoimmune diseases, and it affects over 1 percent of the population. Although many anti-arthritis drugs are available for RA therapy, their long-term use may lead to severe adverse effects. This, combined with high cost of many newer drugs, poses a hurdle for the effective control of RA as well as patient compliance with therapeutic regimens. Therefore, novel treatment modalities are required to overcome these limitations. In this context, we have developed a nanotechnology-based drug delivery system for targeted therapy of arthritic inflammation. Liposomal entrapment of drugs increases their shelf-life in vivo, whereas the display of a joint-homing peptide ligand on liposomal surface aids in guiding them to the site of inflammation. One such peptide (denoted as ART-1) was previously identified by us by phage peptide-display library screening of arthritic Lewis rats. When administered subcutaneously or intravenously, fluorescence-labeled ART-1 shows preferential homing to arthritic joints compared to normal (control) joints. We exploited this drug delivery system for the treatment of experimental arthritis with dexamethasone (Dex) using the rat adjuvant arthritis (AA) model. At the time of onset of AA, rats were treated with liposomal Dex, unpackaged (free) Dex, or the vehicle on alternate days. All rats were observed and graded regularly for arthritis severity. Sera obtained at the terminal step were tested for a panel of enzymes indicating tissue/organ toxicity. Liposomal Dex showed improved therapeutic profile (efficacy/toxicity ratio) over that of free Dex. We propose that this peptide ligand-targeted drug delivery approach can be adapted for effective control of human RA. "Supported by grants from NIH (R01 AT004321), Veterans Affairs (5 I01 BX002424) and Silo Pharma"

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Persidis, Aris. „Arthritis drug discovery“. Nature Biotechnology 17, Nr. 7 (Juli 1999): 726–28. http://dx.doi.org/10.1038/10954.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

&NA;, &NA;. „Arthritis Drug Update“. Orthopaedic Nursing 10, Nr. 4 (Juli 1991): 88. http://dx.doi.org/10.1097/00006416-199107000-00013.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Nanjaiah, Hemalatha, und Kamal D. Moudgil. „The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy“. International Journal of Molecular Sciences 24, Nr. 8 (07.04.2023): 6883. http://dx.doi.org/10.3390/ijms24086883.

Der volle Inhalt der Quelle

Annotation:

Liposomes and other types of nanoparticles are increasingly being explored for drug delivery in a variety of diseases. There is an impetus in the field to exploit different types of ligands to functionalize nanoparticles to guide them to the diseased site. Most of this work has been conducted in the cancer field, with relatively much less information from autoimmune diseases, such as rheumatoid arthritis (RA). Furthermore, in RA, many drugs are self-administered by patients subcutaneously (SC). In this context, we have examined the attributes of liposomes functionalized with a novel joint-homing peptide (denoted ART-1) for arthritis therapy using the SC route. This peptide was previously identified following phage peptide library screening in the rat adjuvant arthritis (AA) model. Our results show a distinct effect of this peptide ligand on increasing the zeta potential of liposomes. Furthermore, liposomes injected SC into arthritic rats showed preferential homing to arthritic joints, following a migration profile in vivo similar to that of intravenously injected liposomes, except for a less steep decline after the peak. Finally, liposomal dexamethasone administered SC was more effective than the unpackaged (free) drug in suppressing arthritis progression in rats. We suggest that with suitable modifications, this SC liposomal treatment modality can be adapted for human RA therapy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Bhavani J, Ravichandran S, Satheesh Kumar D, Chandrasekaran A R, Saraladevi V und Irfana Asma S. „Investigation and Preparation of Polyherbal Ointment for Arthritis“. International Journal of Pharmaceutical Research and Life Sciences 6, Nr. 2 (25.12.2018): 34–37. http://dx.doi.org/10.26452/ijprls.v6i2.1252.

Der volle Inhalt der Quelle

Annotation:

The process of inflammation and the arthritis was induced due to the immune system problems in elderly patients. They are encountering problems with the immune system which identifies the own body as a foreign system and acts against it. This causes inflammation in the joints and therefore causing pain and swelling in the joints. This immunity lowering drugs are the major classes of drugs that will affect the human body by lowering the immunity, and the side effects are caused by the opportunistic infections that occur when the body has low immunity. These effects are now dangerous, and the drugs that treat arthritis are now considered deadly, and their use is minimized too. In this respect, the herbs are found to be the best sources of the treatment of arthritis that produce the chemical constituents that target and cure inflammation that causes arthritis. The plant extract was used to incorporate into the ointment, and this was investigated for the anti-arthritic activity. This was compared to the activity of the extract and standard drug. The ointment that was prepared showed a significantly better activity compared with the standard drug.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Li, Ting, Kangsheng Liao, Yuxin Zhuang, Jianlin Wu und Juan Liu. „C15 is actionable drug target for anti-arthritis via activation Nrf2 signaling“. Journal of Immunology 202, Nr. 1_Supplement (01.05.2019): 133.12. http://dx.doi.org/10.4049/jimmunol.202.supp.133.12.

Der volle Inhalt der Quelle

Annotation:

Abstract SNM is a purified compound isolated from Chinese Medicinal plant. In the current study, we found that SNM not only ameliorated the progression of collagen induced arthritis (CIA), but protected joints from destruction in mice, indicating that SNM probably restricted the local inflammation of arthritic joints. As synovium in the joints is the major target tissue of rheumatoid arthritis, the synovium fibroblasts derived from RA patients (RASFs) were employed to validate the anti-arthritic effect and explore underlying mechanism of SNM. The results demonstrated that SNM significantly inhibited IL-6 and IL-33 secretion, COX-2 expression and ROS production in RASFs. Mass spectrometry results demonstrated that cysteine 26 (C26) and lysine 873 (K873) of C15 are a direct target of SNM. Underlying mechanistic study showed that knockdown C15 resulted in the accumulation and phosphorylation of p62 and aggregation of Nrf2 and HO-1 in cytoplasma of RASFs. Consistently, SNM activated p62/Nrf2 signaling in RASFs via covalently binding at C26 and K873 of C15. Furthermore, the collagen antibody-induced arthritis (CAIA) model was established in Nrf2−/− mice to verify the role of Nrf2 in the anti-arthritic effect of SNM, and the results explored that Nrf2−/− mice are resistant to the anti-arthritic effect of SNM. Our findings explored that C15 is an actionable drug target for anti-arthritis via activation Nrf2 signaling.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

K., Neha, und Ravi Shankar M. „Prescribing patterns in the management of arthritis in a rural tertiary care teaching hospital“. International Journal of Basic & Clinical Pharmacology 10, Nr. 1 (23.12.2020): 49. http://dx.doi.org/10.18203/2319-2003.ijbcp20205537.

Der volle Inhalt der Quelle

Annotation:

Background: Based on 2003 National Health Insurance Scheme (NHIS) data, a projected 67 million (25%) adults aged 18 years or older will have arthritis and 25 million (37%) of those will have arthritis-attributable activity limitations by the year 2030. Objective of this study is to know the prevalence of different types of arthritis, current trends of drug prescribing patterns in its management and to create awareness about rational use of drugs in a rural tertiary care hospital.Methods: This was an observational study of drug prescriptions among 100 arthritis patients in a tertiary care teaching hospital, India. Patients diagnosed with arthritis with or without co-morbidities were enrolled in the study considering the inclusion and exclusion criteria with a verbal informed consent.Results: Out of 100 arthritis cases, prevalence of Osteoarthritis (OA) was seen more than Rheumatoid arthritis (RA). Osteoarthritis was more commonly seen in males and RA in females. Arthritis was more prevalent in the age group of 36-65 years. Oral route was the most preferred route of administration of drugs and Nonsteroidal anti-inflammatory drugs (NSAIDs) were the first choice. Vitamin D3+ calcium was the most commonly prescribed drug in arthritis. Diclofenac was the most commonly used drug for monotherapy in OA and methotrexate in RA.Conclusions: In this study, some patients diagnosed with RA were treated with NSAIDs as first line and no Disease Modifying Anti-Rheumatic Drugs (DMARD) were given. This irrational prescribing trend should be changed. Non-pharmacological treatment has a qualitative role in treating arthritis and should be advised instead of multiple drug therapy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Chakraborty, Debpratim, Nisha Lama Yolmo und Nisha Lama Yolmo. „COSTUS SPECIOSUS AND ITS ANTIPSORIATIC ARTHRITIS ACTIVITY: A REVIEW“. Asian Journal of Pharmaceutical and Clinical Research 12, Nr. 1 (07.01.2019): 30. http://dx.doi.org/10.22159/ajpcr.2018.v12i1.20430.

Der volle Inhalt der Quelle

Annotation:

Objective: Psoriatic arthritis is an autoimmune disease. The marketed drugs cannot totally cure the disease state as well as they have severe side effects and for that reason researcher and scientists are going for traditional medicines. Costus speciosus is the plant of choice for its several positive activities against psoriatic arthritis.Methods: Wistar albino healthy rat was taken for 0.1 ml of Freund adjuvant-induced anti-arthritic and anti-inflammatory test, and diclofenac sodium (15 mg/kg) was taken as standard drug. The paw volume was measured at different time 1st, 7th, 14th, and 21st days of experiment. In another study, the protocol is same, but indomethacin (10 mg/kg) was taken as standard drug. Another study was performed to know that the plant drug has any lipopolysaccharide (LPS)-stimulated COX-protein inhibitor activity or not. An acute anti-inflammatory property was studied in carrageenan-induced paw edema and result is measured by plethysmometer. The chronic anti-inflammatory property was studied by cotton pellet-induced granuloma formation. 400 mg/kg and 800 mg/kg dose of ethanolic extract is administered to the animal of both acute and chronic studies.Results: In anti-arthritic and anti-inflammatory study, after the 21st day, it has found that standard drug (diclofenac sodium) decreases paw volume 40 % where the plant drug reduces it 68.33% & 75.50% at higher and lower dose respectively. In the other study the Standard drug (Indomethacin) show arthritic score of 0.83 and the extract shows 1.67 at its higher concentration. In LPS-stimulated cyclooxygenase-2 (COX-2) inhibition study, extract helps to decrease the LPS-stimulated COX-2 protein nearly similar as methotrexate without any side effect. In the cotton pallet-induced anti-inflammatory study, 400 mg/kg and 800 mg/kg dose of ethanolic extract shows similar result against standard drug.Conclusion: Although its activity is less compared to the marketed drug, in the other sides, it has very mild adverse effect compared to the marketed Drug. It can be used as a supportive drug in the treatment of Psoriatic arthritis and by chemical modification the activity may be increased without any side effect.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Chakraborty, Debpratim, Nisha Lama Yolmo und Nisha Lama Yolmo. „COSTUS SPECIOSUS AND ITS ANTIPSORIATIC ARTHRITIS ACTIVITY: A REVIEW“. Asian Journal of Pharmaceutical and Clinical Research 12, Nr. 1 (07.01.2019): 30. http://dx.doi.org/10.22159/ajpcr.2019.v12i1.20430.

Der volle Inhalt der Quelle

Annotation:

Objective: Psoriatic arthritis is an autoimmune disease. The marketed drugs cannot totally cure the disease state as well as they have severe side effects and for that reason researcher and scientists are going for traditional medicines. Costus speciosus is the plant of choice for its several positive activities against psoriatic arthritis.Methods: Wistar albino healthy rat was taken for 0.1 ml of Freund adjuvant-induced anti-arthritic and anti-inflammatory test, and diclofenac sodium (15 mg/kg) was taken as standard drug. The paw volume was measured at different time 1st, 7th, 14th, and 21st days of experiment. In another study, the protocol is same, but indomethacin (10 mg/kg) was taken as standard drug. Another study was performed to know that the plant drug has any lipopolysaccharide (LPS)-stimulated COX-protein inhibitor activity or not. An acute anti-inflammatory property was studied in carrageenan-induced paw edema and result is measured by plethysmometer. The chronic anti-inflammatory property was studied by cotton pellet-induced granuloma formation. 400 mg/kg and 800 mg/kg dose of ethanolic extract is administered to the animal of both acute and chronic studies.Results: In anti-arthritic and anti-inflammatory study, after the 21st day, it has found that standard drug (diclofenac sodium) decreases paw volume 40 % where the plant drug reduces it 68.33% & 75.50% at higher and lower dose respectively. In the other study the Standard drug (Indomethacin) show arthritic score of 0.83 and the extract shows 1.67 at its higher concentration. In LPS-stimulated cyclooxygenase-2 (COX-2) inhibition study, extract helps to decrease the LPS-stimulated COX-2 protein nearly similar as methotrexate without any side effect. In the cotton pallet-induced anti-inflammatory study, 400 mg/kg and 800 mg/kg dose of ethanolic extract shows similar result against standard drug.Conclusion: Although its activity is less compared to the marketed drug, in the other sides, it has very mild adverse effect compared to the marketed Drug. It can be used as a supportive drug in the treatment of Psoriatic arthritis and by chemical modification the activity may be increased without any side effect.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "ARTHRITIS DRUG"

1

Allen, Rosamund Elizabeth. „Liposomes as drug delivery systems“. Thesis, University of Essex, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.352982.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Webster, Amy Philomena. „Epigenetics of response to biologic drug therapy in rheumatoid arthritis“. Thesis, University of Manchester, 2015. https://www.research.manchester.ac.uk/portal/en/theses/epigenetics-of-response-to-biologic-drug-therapy-in-rheumatoid-arthritis(d1518a5c-ef1c-4d8f-b210-8a2342139a45).html.

Der volle Inhalt der Quelle

Annotation:

Background: Rheumatoid arthritis (RA) is a common complex autoimmune disorder which is influenced by both genetic and environmental factors. While multiple factors that influence susceptibility to and outcome of disease have been identified there is still a large proportion of missing heritability and limited understanding of disease pathogenesis. In recent years, biologic drug therapies have advanced treatment of RA; however good disease control is achieved in just 30% of patients, making identification of predictors of treatment response important. One area of research which is yet to be explored in relation to treatment response, and requires further evaluation in RA susceptibility, is epigenetics. Epigenetics is the study of modifications of the DNA which can influence gene expression but do not alter genetic sequence, and the most commonly studied epigenetic phenomenon, to date, is DNA methylation. Objectives: To identify DNA methylation signatures predictive of treatment response to anti-TNF biologics, to explore the role of DNA methylation in RA susceptibility using disease discordant monozygotic (MZ) twins, and to assess the effect of cryopreservation of cells on DNA methylation. Methods: Genome-wide DNA methylation levels were measured using the HumanMethylation450 BeadChip in pre-treatment whole blood DNA samples from individuals who had extremely good or extremely poor response to the anti-TNF therapies, etanercept and adalimumab, and in MZ twins discordant for RA (n=79 pairs). I also compared genome-wide methylation in cells which had been cryopreserved with fresh cells, to investigate if this technique is suitable for epigenetic investigations. Results: I identified four methylation sites which were significantly related to response to etanercept at a false discovery rate of 5%, the most significantly differentially methylated of which maps to the LRPAP1 gene (p=1.46E-8). Indeed, four other sites at the same locus also showed evidence for differential methylation indicating that this represents a differentially methylated region. No sites were significantly associated with response to adalimumab after correction for multiple testing. I identified subtle differences in DNA methylation between RA discordant twins. Although these were not statistically significant following adjustment for cell composition, one of the most differentially methylated positions mapped to the ZNF74 gene (p=4.97E-6), and replicated a methylation difference identified in the largest previous epigenome-wide association study of RA cases and unrelated healthy controls. I found that cryopreservation of cells does not significantly alter the methylome, an important observation that will impact upon design of future studies. Conclusions: In the largest studies of DNA methylation in RA treatment response and RA discordant MZ twins to date, I identified significant differential methylation in etanercept response, but not adalimumab response, and found small differences in methylation in RA discordant MZ twins. I also concluded that cryopreservation does not significantly alter the methylome.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Vugler, Alexander David. „Predicting anti-arthritic drug effects in collagen-induced arthritis using short-term mechanistic models of collagen II immunity“. Thesis, Open University, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.494617.

Der volle Inhalt der Quelle

Annotation:

Novel anti-arthritic drugs are often assessed in murine collagen-induced arthritis (CIA), which is a widely used pre-clinical model of rheumatoid arthritis. However, CIA studies are lengthy, development of arthritis is not synchronised and not all animals develop disease. Work conducted in this thesis addressed some of these issues by developing short-term mechanistic models of collagen II (CII) immunity. Drug effects on Cll-induced hypersensitivity, anti-CII antibodies and ex vivo CII stimulated CD4⁺ T cell proliferation in mice 14 days post-CII sensitisation were assessed and compared to their anti-arthritic effect in CIA.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Gregg, Catherine Nicola. „Structure-activity studies in non-steroidal anti-inflammatory drugs“. Thesis, Liverpool John Moores University, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.238686.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Speirs, A. „Gold chemistry and its use in the treatment of rheumatoid arthritis“. Thesis, University of Strathclyde, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.371977.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Mina, James. „Hyaluronic acid based polymer drug conjugates for the treatment of rheumatoid arthritis“. Thesis, University of the West of Scotland, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739391.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Kou, Eric Yao-Chung. „Child resistant drug packaging and arthritis can older consumers access their medications? /“. Diss., Connect to online resource - MSU authorized users, 2006.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Dunagan, Fiona M. „Non-steroidal anti-inflammatory drugs : pharmacokinetics and clinical response in rheumatoid arthritis“. Thesis, University of Glasgow, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.236497.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Singh, Jennifer. „Polymer-drug conjugates based on hyaluronic acid for the treatment of rheumatoid arthritis“. Thesis, University of the West of Scotland, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415937.

Der volle Inhalt der Quelle

Annotation:

The work represents an initial appraisal ofhow polymer-drug conjugates based upon hyaluronic acid (HA) may behave at sites of inflammation relative to unmodified HA. Three polymer drug conjugates were synthesized in which a model drug, p-nitroaniline (pNA) has been joined to HA via a peptide spacer group containing alanine (ala) and valine (val). The conjugates are: HA-ala-pNA, HA-val-ala-pNA, and HA-ala-ala-ala-pNA. Each of the conjugates was subjected to the degradative effects of both hyaluronidase and hydroxyl radicals by the Fenton reaction (generated by Fe2 + ions and H202) . Hyaluronidase digestion was followed both by measurement of reducing hexosamine end-groups and rheologically. The degradative effects of hydroxyl radicals were followed by rheology alone. On incubation with hyaluronidase, end-group analysis showed that the rate of degradation of HA-ala-ala-ala-pNA preparation did not appear to differ significantly from that of unmodified HA. The hyaluronic acid-val-ala-pNA sample appeared to show a higher degradation rate than HA itself initially, after which it slowed relative to HA itself. With HA-ala-pNA the rate of hydrolysis of the HA backbone was found to be considerably lower that that observed for the other materials. Viscometric studies on the effects of hydroxyl radicals showed that, as expected, the rate of decrease in viscosity of the unmodified HA increased with increasing [Fe2J and that H202 alone showed a depolymerising effect on the HA in a concentration-dependent manner. The initial viscosity of the HA-ala-pNA and HA-ala-ala-ala-pNA was considerably lower than that of the unmodified H.-and hence any degradation was difficult to follow although some effects could Q\? observed with the higher concentrations of Fe::+. The HA-\al-ala-pNA conjugate showed a higher initial viscosity than native HA. The reason for this is not clear and would require more experimentation. Like the unmodified hyaluronic acid, on exposure to hydroxyl radicals, a rapid initial depolymerization of the conjugates was observed the rate of which increased with increasing concentration of Fe:!+.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Walker, K. A. „An investigation into the mechanisms responsible for altered drug disposition in adjuvant-induced arthritis“. Thesis, University of Aberdeen, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.372625.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Bücher zum Thema "ARTHRITIS DRUG"

1

Hills, Margaret. Treating arthritis: The drug free way. 2. Aufl. London: Sheldon Press, 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Sernaqué, Vivienne. The pill book of arthritis. Herausgegeben von Copyright Paperback Collection (Library of Congress), Chilnick Lawrence D, Jaffe Israeli A, Montopoli Daniel und Stern Bert. Toronto: Bantam Books, 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Rheumatoid arthritis. New York: Oxford University Press, 2011.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Arthritis: Types, treatment, and prevention. Hauppauge, N.Y: Nova Science Publishers, 2011.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Hills, Margaret. Curing arthritis: More ways to a drug-free life. Oxford: Clio Press, 1992.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

H, Klippel John, und Arthritis Foundation, Hrsg. Arthritis drugs and more: An A to Z guide from the editors of Arthritis today. Atlanta, GA: Arthritis Foundation, 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

The arthritis handbook: The essential guide to a pain-free, drug-free life. New York: DiaMedica, 2008.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

H, Weisman Michael, und Weinblatt Michael E, Hrsg. Treatment of the rheumatic diseases: Companion to the textbook of rheumatology. Philadelphia: Saunders, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Research & Forecasts, Inc., Hrsg. Arthritis and other chronic pain conditions: Problems associated with drug therapy. New York, N.Y. (110 E. 59th St., New York 10022): Research & Forecasts, 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Theodosakis, Jason. The arthritis cure. New York: St. Martin's Paperbacks, 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Buchteile zum Thema "ARTHRITIS DRUG"

1

Scott, Ian C., James B. Galloway und David L. Scott. „Non-drug Treatments“. In Inflammatory Arthritis in Clinical Practice, 163–72. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6648-1_11.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Scott, Ian C., James B. Galloway und David L. Scott. „Symptomatic Drug Treatment“. In Inflammatory Arthritis in Clinical Practice, 67–85. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6648-1_5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Shah, Neel Jayesh. „Drug Used in Rheumatoid Arthritis“. In Introduction to Basics of Pharmacology and Toxicology, 353–60. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6009-9_20.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Blüml, Stephan, Georg Stummvoll und Josef S. Smolen. „B-Cell Targeted Therapies in Rheumatoid Arthritis“. In Milestones in Drug Therapy, 97–110. Basel: Springer Basel, 2013. http://dx.doi.org/10.1007/978-3-0348-0706-7_6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Ali, Syed Salman, Snigdha Bhardwaj, Najam Ali Khan, Syed Sarim Imam und Chandra Kala. „Phytoconstituent-Loaded Nanomedicines for Arthritis Management“. In Biomarkers as Targeted Herbal Drug Discovery, 177–206. First edition.: Apple Academic Press, 2021. http://dx.doi.org/10.1201/9781003045526-8.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Nandakumar, Kutty Selva. „Antibody-Mediated Arthritis and New Therapeutic Avenues“. In Antibody-Mediated Drug Delivery Systems, 407–26. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118229019.ch20.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Aluko, Atinuke, und Prabha Ranganathan. „Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis“. In Methods in Molecular Biology, 527–67. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2573-6_19.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Dugger, Robert W., Mark E. Flanagan und Rajappa Vaidyanathan. „Tofacitinib (Xeljanz): The First-in-Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis“. In Innovative Drug Synthesis, 283–302. Hoboken, NJ, USA: John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118819951.ch15.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Odisharia, Kakha, Vladimer Odisharia, Paata Tsereteli und Nona Janikashvili. „On the Mathematical Model of Drug Treatment of Rheumatoid Arthritis“. In Springer Proceedings in Mathematics & Statistics, 161–68. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-10419-1_10.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Amjadi, Sogol S., Veena K. Ranganath und Daniel E. Furst. „Disease-Modifying Antirheumatic Drug Use in Older Rheumatoid Arthritis Patients“. In Geriatric Rheumatology, 151–72. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-5792-4_17.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "ARTHRITIS DRUG"

1

SUN, YANG-BO, und ZHI-LI ZENG. „BIBLIOMETRIC ANALYSIS OF METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS“. In 2021 International Conference on Education, Humanity and Language, Art. Destech Publications, Inc., 2021. http://dx.doi.org/10.12783/dtssehs/ehla2021/35713.

Der volle Inhalt der Quelle

Annotation:

[Objective] To analyze the growth rule of literature, core authors, core institutions and Co-word Analysis in the field of methotrexate in the treatment of rheumatoid arthritis, to draw the knowledge map of key words and the cooperation network of authors, and to get the current frontiers and research hotspots through the research and analysis of these indicators, so as to provide reference for future researchers to choose research directions. [Methods] The three databases including CNKI, Wanfangdata and Cqvip were used as retrieval databases, and the key words of "rheumatoid arthritis" and "methotrexate" and their synonyms were used as retrieval keywords. The literature published in the three databases from 2009 to 2018 were retrieved and analyzed by bibliometrics analysis method. [Result] 2404 valid literature were screened out. The growth curve of literature showed a relatively stable upward trend, and formed a stable core group of high-yield authors. The main direction of research in this field in the past ten years was the effectiveness analysis of methotrexate combined with drug treatment for rheumatoid arthritis. [Conclusion] Domestic research on methotrexate in the treatment of rheumatoid arthritis will continue to be the focus of medical research in the next few years. Rheumatoid arthritis (RA) is a chronic systemic immune disease. Its early manifestations are mainly joint pain and dysfunction. It can lead to joint function loss and accompanied by atrophy of bone and skeletal muscle. It has a high disability rate and seriously threatens human physical and mental health [1].The incidence of rheumatoid arthritis was higher in women than in men [2]. According to statistics, the prevalence of rheumatoid arthritis in China is between 0.32% and 0.36% [3]. Therefore, searching for drugs with less side effects and obvious effects is a research hotspot in the medical field [4]. Methotrexate, as a gold standard antirheumatic drug, has been widely used in combination therapy and randomized controlled clinical trials [5]. In order to clearly understand the research and development trend of methotrexate in the field of rheumatoid arthritis, this paper makes bibliometric analysis of the relevant literature published in this field in the past 10 years, and provides reference for the future research and development of this field with objective and real data.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Paul, Jérôme, Pierre Gramme und Thibault Helleputte. „THU0035 DOMINANCE OF DRUG TARGET MECHANISMS IN RHEUMATOID ARTHRITIS“. In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.3115.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Yildirim, Pinar. „Mining Online Drug Reviews Database for the Treatment of Rheumatoid Arthritis by using Deep Learning“. In 3rd International Conference on Data Science and Machine Learning (DSML 2022). Academy and Industry Research Collaboration Center (AIRCC), 2022. http://dx.doi.org/10.5121/csit.2022.121509.

Der volle Inhalt der Quelle

Annotation:

In this paper, a research study for online patient reviews is introduced. Rheumatoid arthritis is a long-term and disabling autoimmune disease. Today, a huge amount of people have rheumatoid arthritis in the world. Considering the importance of the medication of rheumatoid arthritis, we aimed to investigate patient reviews in WebMD database and get some useful information for this disease. Our results revealed that etanercept treatment has the highest number of reviews. Data analysis was applied to discover knowledge on this drug. Deep learning approach was used to predict the effectiveness of etanercept and classification results were compared with other traditional classifiers. According to the comparison of classifiers, deep neural network has better accuracy metrics than others. Therefore, the results highlight that deep learning can be encouraging for medical data analyses. We hope that our study can make contributions to intelligent data analysis in medical domain.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

rad, sahar moazen, Nafiseh Abdolahi und Alireza Soltani. „AB0393 IMPROVING DRUG SOLUBILITY FOR INFLAMMATORY ARTHRITIS TREATMENT: SULFASALAZINE NIOSOME“. In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7821.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Urrego, J., K. Mendez und P. Santos-Moreno. „AB1407-HPR Adverse drug reactions in patients with rheumatoid arthritis“. In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7567.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Rosales Rosado, Z., D. D. Freites NÚÑEZ, C. Lajas Petisco, E. Pato Cour, León Mateos und L. Abásolo Alcázar. „SAT0164 Adverse drug reactions due to disease modifying drugs in patients with incident rheumatoid arthritis“. In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2473.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Karakoc, Y., und I. Ercan. „AB0502 Drug survival analysis of tofacitinib in patients with rheumatoid arthritis“. In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.1893.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Haugeberg, Glenn, Bjørg Tilde Svanes Fevang, Gunnstein Bakland, Erik Rødevand und Andreas Diamantopoulos. „FRI0094 LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG“. In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7387.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Freites Nuñez, D., Z. Rosales, L. León, J. Font, P. Lois, C. Vadillo, E. Pato et al. „SAT0323 Adverse drug reactionsrelated to disease-modifying drugs (DMARD) in psoriatic arthritis patients in daily clinical practice“. In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2577.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Delevallee, L., C. Huynh, JH Salmon, P. Quillet, C. Mongaret, M. Bonnet und D. Hettler. „CP-200 Drug continuation rate of ABATACEPT in patients with rheumatoid arthritis“. In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.198.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "ARTHRITIS DRUG"

1

Donahue, Katrina E., Gerald Gartlehner, Elizabeth R. Schulman, Beth Jonas, Emmanuel Coker-Schwimmer, Sheila V. Patel, Rachel Palmieri Weber, Kathleen N. Lohr, Carla Bann und Meera Viswanathan. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Agency for Healthcare Research and Quality (AHRQ), Juli 2018. http://dx.doi.org/10.23970/ahrqepccer211.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Layegh, Zohra, Charlotte Krieckaert, Pascal de Jong und Gertjan Wolbink. Therapeutic drug monitoring in the inflammatory arthritis; Which drug level should we aim for? A systematic literature review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0108.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Olson, Steven A. Development of Intra-Articular Drug Delivery to Alter Progression of Arthritis Following Joint Injury. Fort Belvoir, VA: Defense Technical Information Center, April 2012. http://dx.doi.org/10.21236/ada574477.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Olson, Steven A., Farshid Guilak, Bridgette D. Furman und Kelly A. Kimmerling. Development of Intra-Articular Drug Delivery to Alter Progression of Arthritis Following Joint Injury. Fort Belvoir, VA: Defense Technical Information Center, April 2013. http://dx.doi.org/10.21236/ada581150.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Cockburn, Iain, und Aslam Anis. Hedonic Analysis of Arthritis Drugs. Cambridge, MA: National Bureau of Economic Research, Mai 1998. http://dx.doi.org/10.3386/w6574.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Existing drugs for rheumatoid arthritis may also improve associated fatigue. National Institute for Health Research, August 2016. http://dx.doi.org/10.3310/signal-000282.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate. National Institute for Health Research, Januar 2018. http://dx.doi.org/10.3310/signal-000538.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!